Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Zenshine Pharmaceuticals

Request full access

Small molecule therapeutics for cancer and viral infections

Hangzhou, ChinaFounded 2018Biotech & Life Sciences

About Zenshine Pharmaceuticals

Zenshine Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2018 by industry veterans Jinfu Yang and Xiaolin Alan Hao. The company is headquartered in Nanjing, China, with research operations in Hangzhou and a clinical and business development presence in the San Francisco Bay Area. Zenshine focuses on developing small molecule therapeutics for cancer, viral infections, and inflammation.

The company's strategy involves targeting key biological pathways to interrupt virus replication, block tumor growth directly, and bolster anti-tumor immune responses. Zenshine has built a pipeline of drug candidates, including ZX-101A, a next-generation PI3Kδ/γ inhibitor for hematologic malignancies and solid tumors, and ZX-4081, a PI3Kγ inhibitor for solid tumors. Another key asset is ZX-7101A (Seloxavir Marboxil), a single-dose oral antiviral for influenza A and B. In July 2025, Zenshine received regulatory approval in China to market Seloxavir Marboxil.

Zenshine has secured significant funding through several rounds, including a Series A in December 2020, a Series A+ of over $30 million in May 2021, and subsequent Series B and C rounds in 2023. These funds are being used to advance its pipeline through global clinical trials. The company has received multiple IND (Investigational New Drug) approvals from both the U.S. FDA and China's NMPA, and has progressed several candidates into Phase 1, 2, and 3 clinical trials.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
None listed
Dealroom signal
46.6/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES C✓Equity / VC Oct 2023 $14M $344M Kunlun Capital · Zhonghui Investment · Jiaxing Zhonghui Shengping Venture Capital · Hangzhou Saizhichuang Yunqiqi Venture Capital ↗
SERIES B✓Equity / VC Mar 2023 $14M $248M Ennovation Ventures · Nanjing Yang Zi State-Owned Investment Group · Hankang Capital · Nanjing Jiangbei New District Science and Technology Investment Group ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Zenshine Pharmaceuticals website traffic

Latest recorded traffic for Zenshine Pharmaceuticals is 440 monthly website visits, up 238.5% over the last three months. Zenshine Pharmaceuticals's team grew 9.1% over the past year.

Latest monthly visits440 3-month web change+238.5% 1-year team growth+9.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Zenshine Pharmaceuticals in the Hangzhou ecosystem

Live from Dealroom

The Zenshine Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

17 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A12 investors entered at this stage

  • Jiuyou Capital
  • Nanjing Zijin Technology Venture Capital
  • Indaco Capital
  • Jiakang Venture Capital
  • Matrix Partners China
  • LYZZ Capital
  • State Development & Investment Corporation (SDIC)
  • Ennovation Ventures
  • Nanjing Yang Zi State-Owned Investment Group
  • Hankang Capital
  • Nanjing Jiangbei New District Science and Technology Investment Group
  • Cybernaut

Series B and later5 investors entered at this stage

  • Kunlun Capital
  • Zhonghui Investment
  • Jiaxing Zhonghui Shengping Venture Capital
  • Hangzhou Saizhichuang Yunqiqi Venture Capital
  • Jumpcan
Employees 12 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China83.3%
🇺🇸 United States16.7%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Zenshine Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Zenshine Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.